MedTrace Logo

Clinical Trial to Evaluate Safety, Tolerability and Efficacy of NFX88 in SCI

NCT04148573 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-12-02

No results posted yet for this study

Summary

In summary, this small-scale study is designed to demonstrate that the NFX88 is safe and well tolerated, as well as preliminary evidence of improvement in the score of VAS, PD-Q, and PGIC scales.

Conditions

  • Neuropathic Pain
  • Spinal Cord Injuries

Interventions

DRUG

NFX88 - 1

3 times a day

DRUG

NFX88 - 2

3 times a day

DRUG

NFX88 - 3

3 times a day

DRUG

PLACEBO - 4

3 times a day

Sponsors & Collaborators

  • Neurofix S.L.

    lead INDUSTRY

Principal Investigators

  • ANTONIO OLIVIERO, MD · HOSPITAL DE PARAPLEGICOS DE TOLEDO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2022-05-20
Completion
2022-07-20

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04148573 on ClinicalTrials.gov